Evidence map›Paper›PMID 41857040›Full record

ArticleNPJ Parkinson's disease2026

Age at onset of Parkinson's disease modulates the sphingolipid-dopaminergic interplay in autonomic progression.

Zhinan Ye, Shishu Zhang, Zijia Liu, Junchao Wang, Junjie Li, Xicheng Yu, Xinyi Yuan, Zhuoyu Chen, Zihan Yuan, Ziyu Yang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Zhinan Ye *Department of Neurology, Taizhou Municipal Hospital, Taizhou, Zhejiang, China.
Shishu Zhang *Renji College, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zijia Liu *The Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Junchao WangThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Junjie LiThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xicheng YuThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xinyi YuanThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhuoyu ChenThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zihan YuanThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Ziyu YangThe First School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Suwen HuangDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yiyun WengDepartment of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. wengyiyun2012@126.com.
Dehao YangDepartment of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. dehao_yang@zju.edu.cn.

Funding

National Innovation and Entrepreneurship Training Program for College Students No. 202510343083National Natural Science Foundation of China No. 82302081Science and Technology Plan Project of Taizhou No. 25ywb102Zhejiang Provincial Natural Science Foundation of China No. LQ24H090003
6 · The paper itself

Abstract

To investigate whether age of onset (AAO) affects cerebrospinal fluid (CSF) C16 glucosylceramide (C16 GlcCer) and striatal dopamine transporter-specific binding ratios (DAT-SBRs) in Parkinson's disease (PD), and their associations with longitudinal autonomic and cognitive outcomes, we conducted a large-scale, multicenter, prospective observational cohort study. Late-onset PD (LOPD, AAO > 50 years) patients showed higher baseline CSF C16 GlcCer and lower DAT‑SBR in some striatal regions compared to early‑onset PD (EOPD, AAO ≤ 50 years). Higher DAT-SBR was associated with a lower risk of autonomic dysfunction (AutD) in both groups and with better longitudinal cognitive performance in LOPD. Importantly, only in LOPD did the interaction between C16 GlcCer and DAT‑SBR predict more favorable autonomic progression, independent of CSF α‑synuclein. In EOPD, AutD risk was primarily related to regional DAT loss. These findings suggest that AAO modulates sphingolipid‑dopaminergic crosstalk and supports the combined use of these biomarkers for risk stratification.

Identifiers

PMID41857040
PMCPMC13168328

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.